Loading
A phase 2 trial of Propranolol, Paclitaxel / nab-paclitaxel and Carboplatin in Ovarian cancer, run by Bai-Rong Xia, now recruiting.
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer is a phase 2 interventional study registered as NCT07125391 by Bai-Rong Xia, with 136 participants planned, started 2025-06-20 and due to reach its primary completion in 2026-08-30. Interventions recorded: Propranolol Hydrochloride, Paclitaxel liposome, Carboplatin. Conditions recorded: Ovarian Cancer.
Linked to the drug Propranolol because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Propranolol (Hemangeol) and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/